赛纳生物科技(北京)有限公司

Cygnus Biosciences (Beijing) Co., Ltd., founded in 2015, is a high-tech leader in gene sequencing innovation within the Biotechnology, Health Care, Health and Wellness, and Pharmaceutical industries. The company's slogan, "A high-tech leader in gene sequencing innovation, committed to advanced clinical medicine screening and diagnosis," reflects its dedication to advancing clinical medicine through cutting-edge technology. Its last investment was a Series C round on 20 March 2023, which attracted significant attention from prominent investors including Source Code Capital, Tsinghua Venture Capital, Genertec Venture Capital, Founder H Fund, CCB Capital, and Beijing E-town International Investment & Development. Cygnus Biosciences is positioned as a key player in the field of gene sequencing and clinical diagnostics, with potential for substantial growth and impact within the healthcare and biotechnology sectors.